Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients: an expert delphi analysis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients : an expert delphi analysis. / Østergaard, Svetlana; Møldrup, C.
In: Public Health Genomics, Vol. 13, No. 7-8, 2010.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Anticipated outcomes from introduction of 5-HTTLPR genotyping for depressed patients
T2 - an expert delphi analysis
AU - Østergaard, Svetlana
AU - Møldrup, C
N1 - Copyright © 2010 S. Karger AG, Basel.
PY - 2010
Y1 - 2010
N2 - Objective: The aim of this study was to investigate experts' opinions regarding the extent to which the introduction of pretesting for polymorphism of serotonin transporter promoter region (5-HTTLPR) as a routine intervention in clinical practice would lead to better clinical outcomes for depression patients. Methods: Using an internet survey system, authors of clinical studies addressing the topic of association of 5-HTTLPR genotyping with antidepressant response were contacted to participate in a Delphi study. Results: Responses from 12 experts were used for the final analysis. According to the participants, the introduction of 5-HTTLPR genotyping will lead to 33.8, 48.2, 57.8, and 65.1% of patients reaching remission at 1, 2, 3, and 6 months, respectively. Conclusions: According to experts, application of 5-HTTLPR pretreatment genotyping might influence remission; however, the estimated remission rates with genotyping at first sight do not appear to be superior to existing practice, i.e. without genotyping. It is anticipated that a combination of 5-HTTLPR testing with other genomic variables, which have yet to be determined, and compliance measurements can improve clinical outcomes in the future. At present, the introduction of 5-HTTLPR genotyping is expected to be used only in special situations.
AB - Objective: The aim of this study was to investigate experts' opinions regarding the extent to which the introduction of pretesting for polymorphism of serotonin transporter promoter region (5-HTTLPR) as a routine intervention in clinical practice would lead to better clinical outcomes for depression patients. Methods: Using an internet survey system, authors of clinical studies addressing the topic of association of 5-HTTLPR genotyping with antidepressant response were contacted to participate in a Delphi study. Results: Responses from 12 experts were used for the final analysis. According to the participants, the introduction of 5-HTTLPR genotyping will lead to 33.8, 48.2, 57.8, and 65.1% of patients reaching remission at 1, 2, 3, and 6 months, respectively. Conclusions: According to experts, application of 5-HTTLPR pretreatment genotyping might influence remission; however, the estimated remission rates with genotyping at first sight do not appear to be superior to existing practice, i.e. without genotyping. It is anticipated that a combination of 5-HTTLPR testing with other genomic variables, which have yet to be determined, and compliance measurements can improve clinical outcomes in the future. At present, the introduction of 5-HTTLPR genotyping is expected to be used only in special situations.
KW - Former Faculty of Pharmaceutical Sciences
U2 - 10.1159/000313467
DO - 10.1159/000313467
M3 - Journal article
C2 - 20606382
VL - 13
JO - Public Health Genomics
JF - Public Health Genomics
SN - 1662-4246
IS - 7-8
ER -
ID: 20920560